Headlines about Alexion Pharmaceuticals (NASDAQ:ALXN) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.5141901334621 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news articles that may have effected Accern’s scoring:
- Shares Running on Volume: Alexion Pharmaceuticals Inc (ALXN) – Evergreen Caller (evergreencaller.com)
- Putting Alexion Pharmaceuticals Inc (ALXN) Under the Microscope: Technicals Watch – Evergreen Caller (evergreencaller.com)
- Alexion Pharmaceuticals Raised 2017 Earnings Guidance (finance.yahoo.com)
- Alexion Pharmaceuticals: Modest Growth Projections (finance.yahoo.com)
- At a Pivot Point? Share Update on Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Valero Energy Corporation … – FLBC News (flbcnews.com)
Alexion Pharmaceuticals (ALXN) opened at 136.85 on Thursday. The company has a market cap of $30.54 billion, a PE ratio of 59.35 and a beta of 1.41. The stock has a 50 day moving average of $127.14 and a 200 day moving average of $122.87. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $145.42.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The business had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. During the same quarter in the previous year, the firm earned $1.13 earnings per share. The company’s revenue was up 21.1% on a year-over-year basis. Equities research analysts predict that Alexion Pharmaceuticals will post $5.60 EPS for the current fiscal year.
A number of research firms have recently weighed in on ALXN. BidaskClub raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price on the stock in a research report on Wednesday, August 2nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $168.00 target price (up from $159.00) on shares of Alexion Pharmaceuticals in a research report on Friday, July 28th. Leerink Swann upped their target price on shares of Alexion Pharmaceuticals from $136.00 to $170.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. raised shares of Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 target price on the stock in a research report on Friday, July 28th. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $156.89.
In related news, Director Ann M. Veneman sold 700 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the sale, the director now owns 6,315 shares in the company, valued at $869,828.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average price of $116.32 per share, for a total transaction of $156,910,445.60. The disclosure for this purchase can be found here. Insiders have bought 2,019,734 shares of company stock worth $235,606,846 in the last 90 days. Insiders own 4.35% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.